Medical College of Wisconsin
Medical College of Wisconsin Cancer Center

Translational Metabolomics Shared Resource (TraMSR)

The Translational Metabolomics Shared Resource supports cancer metabolism research, spanning from the analysis of molecules to organelles, to cells and tissues.

Scheduling, Location, and Hours of Operation

Mass Spectrometry: Translational and Biomedical Research Center, 2nd floor
Redox and Bioenergetics: MACC Fund Research Center, 2nd floor
Preclinical and Clinical Imaging: Medical Imaging Research Center, 1st floor
Monday–Friday from 8 a.m.-5 p.m.
Submit a TraMSR iLab request

Services and Technologies

TraMSR provides expertise and services in 1) mass spectrometry (MS) analyses of the tumor metabolome; 2) bioenergetic and redox function analyses; 3) imaging of preclinical models; and 4) quantitative MRI-based clinical response assessments for monitoring patients on clinical trials.  

all
Mass Spectrometry
  • MS sample preparation
  • MS instrumentation: Bruker timsTOF Flex MALDI imaging; Thermo Exploris 240, Waters XEVO
  • MS-based omics analysis: lipidomics, glycomics, glycoproteomics, metabolomics
Redox and Bioenergetics
  • Redox: ROS measurements; GSH/GSSG measurements; redox immunoblotting
  • Metabolism: metabolic pathway profiling; mitochondrial oxygen consumption; glycolytic function; mitochondrial membrane potential; metabolic reprogramming
  • Instrumentation: Agilent Seahorse extracellular flux analyzers; HPLC and UHPLC systems; electron paramagnetic resonance (EPR) and luminescence spectrometers
Preclinical Imaging
  • IVIS SpectrumCT: small animal bioluminescence and fluorescence, low dose X ray microCT and Cherenkov Luminescence imaging
  • Small animal near-infrared (NIR) and short-wave infrared imaging (SWIR)
Clinical Imaging
  • Patient tumor and lymph node measurements and volumetrics
  • Clinical trial level reporting and audit support
  • Cloud-based image repository and tools

Leadership

headshot

Peter LaViolette, PhD

Director, Translational Metabolomics Shared Resource (TraMSR)

plaviole@mcw.edu

View Profile

Notable Publications

Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response. (Bobholz SA, Hoefs A, Hamburger J, Lowman AK, Winiarz A, Duenweg SR, Kyereme F, Connelly J, Coss D, Krucoff M, Banerjee A, LaViolette PS) J Neurooncol 2024 Apr;167(2):243. PMID: 38498261; PMCID: PMC11023959; DOI: 10.1007/s11060-024-04641-2; Scopus ID: 2-s2.0-85187929260

Regulation of immunomodulatory networks by Nrf2-activation in immune cells: Redox control and therapeutic potential in inflammatory diseases. (Pant T, Uche N, Juric M, Zielonka J, Bai X) Redox Biol 2024 Apr;70:103077. PMID: 38359749; PMCID: PMC10877431; DOI: 10.1016/j.redox.2024.103077; Scopus ID: 2-s2.0-85185554817

Noninvasive Autopsy-Validated Tumor Probability Maps Identify Glioma Invasion Beyond Contrast Enhancement. (Bobholz SA, Lowman AK, Connelly JM, Duenweg SR, Winiarz A, Nath B, Kyereme F, Brehler M, Bukowy J, Coss D, Lupo JM, Phillips JJ, Ellingson BM, Krucoff MO, Mueller WM, Banerjee A, LaViolette PS) Neurosurgery 2024 Mar 19. PMID: 38501824; DOI: 10.1227/neu.0000000000002898

Health position paper and redox perspectives - Disease burden by transportation noise. (Sørensen M, Pershagen G, Thacher JD, Lanki T, Wicki B, Röösli M, Vienneau D, Cantuaria ML, Schmidt JH, Aasvang GM, Al-Kindi S, Osborne MT, Wenzel P, Sastre J, Fleming I, Schulz R, Hahad O, Kuntic M, Zielonka J, Sies H, Grune T, Frenis K, Münzel T, Daiber A) Redox Biol 2024 Feb;69:102995. PMID: 38142584; PMCID: PMC10788624; DOI: 10.1016/j.redox.2023.102995; Scopus ID: 2-s2.0-85180606610

Quantitative Histomorphometric Features of Prostate Cancer Predict Patients Who Biochemically Recur Following Prostatectomy. (Duenweg SR, Brehler M, Lowman AK, Bobholz SA, Kyereme F, Winiarz A, Nath B, Iczkowski KA, Jacobsohn KM, LaViolette PS) Lab Invest 2023 Dec;103(12):100269. PMID: 37898290; PMCID: PMC10872376; DOI: 10.1016/j.labinv.2023.100269; Scopus ID: 2-s2.0-85181176849

T2-Weighted MRI Radiomic Features Predict Prostate Cancer Presence and Eventual Biochemical Recurrence. (Duenweg SR, Bobholz SA, Barrett MJ, Lowman AK, Winiarz A, Nath B, Stebbins M, Bukowy J, Iczkowski KA, Jacobsohn KM, Vincent-Sheldon S, LaViolette PS) Cancers (Basel) 2023 Sep 06;15(18). PMID: 37760407; PMCID: PMC10526331; DOI: 10.3390/cancers15184437; Scopus ID: 2-s2.0-85172781879

Carvedilol Phenocopies PGC-1α Overexpression to Alleviate Oxidative Stress, Mitochondrial Dysfunction and Prevent Doxorubicin-Induced Toxicity in Human iPSC-Derived Cardiomyocytes. (Uche N, Dai Q, Lai S, Kolander K, Thao M, Schibly E, Sendaydiego X, Zielonka J, Benjamin IJ) Antioxidants (Basel) 2023 Aug 09;12(8). PMID: 37627583; PMCID: PMC10451268; DOI: 10.3390/antiox12081585; Scopus ID: 2-s2.0-85169136890

Antiproliferative effects of mitochondria-targeted N-acetylcysteine and analogs in cancer cells. (Cheng G, Hardy M, Kalyanaraman B) Sci Rep 2023 May 04;13(1):7254. PMID: 37142668; PMCID: PMC10160116; DOI: 10.1038/s41598-023-34266-w; Scopus ID: 2-s2.0-85158068757

Developing small-diameter vascular grafts with human amniotic membrane: long-term evaluation of transplantation outcomes in a small animal model. (Wang B, Wang X, Kenneth A, Drena A, Pacheco A, Kalvin L, Ibrahim ES, Rossi PJ, Thatcher K, Lincoln J) Biofabrication 2023 Jan 30;15(2). PMID: 36626826; DOI: 10.1088/1758-5090/acb1da; Scopus ID: 2-s2.0-85147095444

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. (Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR) Haematologica 2023 Jan 01;108(1):250-256. PMID: 36106394; PMCID: PMC9827178; DOI: 10.3324/haematol.2022.281309; Scopus ID: 2-s2.0-85145424654

Fluorinated triphenylphosphonium analogs improve cell selectivity and in vivo detection of mito-metformin. (AbuEid M, Keyes RF, McAllister D, Peterson F, Kadamberi IP, Sprague DJ, Chaluvally-Raghavan P, Smith BC, Dwinell MB) iScience 22 December 2022;25(12). DOI: 10.1016/j.isci.2022.105670; Scopus ID: 2-s2.0-85143723525

Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation.’ (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885, (S1083879120304146), (10.1016/j.bbmt.2020.07.005)] Transplantation and Cellular Therapy October 2022;28(10):717. PMID: 36202527; DOI: 10.1016/j.jtct.2021.01.005; Scopus ID: 2-s2.0-85101258094

Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness.(McGarry SD, Brehler M, Bukowy JD, Lowman AK, Bobholz SA, Duenweg SR, Banerjee A, Hurrell SL, Malyarenko D, Chenevert TL, Cao Y, Li Y, You D, Fedorov A, Bell LC, Quarles CC, Prah MA, Schmainda KM, Taouli B, LoCastro E, Mazaheri Y, Shukla-Dave A, Yankeelov TE, Hormuth DA 2nd, Madhuranthakam AJ, Hulsey K, Li K, Huang W, Huang W, Muzi M, Jacobs MA, Solaiyappan M, Hectors S, Antic T, Paner GP, Palangmonthip W, Jacobsohn K, Hohenwalter M, Duvnjak P, Griffin M, See W, Nevalainen MT, Iczkowski KA, LaViolette PS) J Magn Reson Imaging 2022 Jun;55(6):1745-1758. PMID: 34767682; PMCID: PMC9095769; DOI: 10.1002/jmri.27983; Scopus ID: 2-s2.0-85118887092

Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone. (Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M) Adv Sci (Weinh) 2022 Apr;9(12):e2101267. PMID: 35243806; PMCID: PMC9036031; Scopus ID: 2-s2.0-85125564839 

Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. (Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P) Cancer Res 2021 Oct 15;81(20):5336-5352. PMID: 34380633; PMCID: PMC8530981; Scopus ID: 2-s2.0-85116424540

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H) Lancet Oncol 2021 Sep;22(9):1290-1300. PMID: 34339623; DOI: 10.1016/S1470-2045(21)00336-3; Scopus ID: 2-s2.0-85113412076

Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. (Gao X, Qin S, Wu Y, Chu C, Jiang B, Johnson RH, Kuang D, Zhang J, Wang X, Mehta A, Tew KD, Leone GW, Yu XZ, Wang H) J Clin Invest 2021 Aug 16;131(16). PMID: 34255748; PMCID: PMC8363288; Scopus ID: 2-s2.0-85113146308 

WDR26 and MTF2 are therapeutic targets in multiple myeloma. (Sun F, Cheng Y, Riordan JD, Dupuy A, Dubois W, Pisano M, Dong J, Mock B, Zhan F, Hari P, Janz S) J Hematol Oncol 2021 Dec 07;14(1):203. PMID: 34876184; PMCID: PMC8650373; Scopus ID: 2-s2.0-85120899924 

AMPK-deficiency forces metformin-challenged cancer cells to switch from carbohydrate metabolism to ketogenesis to support energy metabolism. (Palma FR, Ratti BA, Paviani V, Coelho DR, Miguel R, Danes JM, Zaichik SV, de Abreu AL, Silva SO, Chen Y, Silverstein RL, Karan U, Jones DP, Bonini MG) Oncogene 2021 Sep;40(36):5455-5467. PMID: 34290400; PMCID: PMC8669831; DOI: 10.1038/s41388-021-01943-x; Scopus ID: 2-s2.0-85110982210